Deisseroth, A B <br/><br/>
Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial.  [electronic resource] 

 -  Human gene therapy  Feb 1996 
 - 401-16 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1043-0342 
<br/><br/><label>Standard No.: </label>10.1089/hum.1996.7.3-401  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP Binding Cassette Transporter, Subfamily B, Member 1--genetics<br/>Adult<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bone Marrow Diseases--chemically induced<br/>Breast Neoplasms--drug therapy<br/>Carmustine--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>DNA, Complementary--administration & dosage<br/>DNA, Recombinant--administration & dosage<br/>Defective Viruses--genetics<br/>Drug Resistance, Neoplasm--genetics<br/>Ethics, Medical<br/>Feasibility Studies<br/>Female<br/>Granulocyte Colony-Stimulating Factor--pharmacology<br/>Hematopoietic Stem Cell Transplantation<br/>Hematopoietic Stem Cells--drug effects<br/>Humans<br/>Interleukin-3--pharmacology<br/>Interleukin-6--pharmacology<br/>Mesna--administration & dosage<br/>Middle Aged<br/>Paclitaxel--administration & dosage<br/>Pilot Projects<br/>Recombinant Fusion Proteins--metabolism<br/>Retroviridae--genetics<br/>Safety<br/>Thiotepa--administration & dosage